Kenya Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Kenya Breast Cancer Therapeutics Market Analysis

$ 3999

The Kenya breast cancer therapeutics market is projected to grow from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of xx% for the year 2022-2030 due to the rising prevalence of breast cancer cases in Kenya. The market is segmented by therapy, by cancer type, and by distribution channel. Sphinx Pharmaceuticals, Pfizer, and Celgene are some major competitors in the Kenya breast cancer therapeutics market.

ID: IN10KEPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Parul Choudhary

Buy Now

Kenya Breast Cancer Therapeutics Market Executive Analysis

The Kenya breast cancer therapeutics market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. The expected cost of the 2022–23 budget in Kenya was $29 Bn, which was $3.03 Bn less than the estimated cost of the 2021/22 fiscal year, which was $32 Bn, of which the health sector received $1.05 Bn. To finance initiatives and programs aimed at achieving universal health coverage, $410 Mn was allotted. $61 Mn was used to purchase COVID-19 vaccines, and $36 Mn went toward the free maternity care program.

Breast cancer is the most prevalent cancer among Kenyan women, with an age-standardized incidence rate of 40.3 cases per 100,000 women. Kenya reported a death rate from breast cancer of 7.1 per 100,000 females in 2013. The combination of an increase in life expectancy and the adoption of unhealthy lifestyles may be to blame for the increased incidence of cancer, especially in older populations. Unhealthy eating practices, drinking alcohol, and using tobacco, as well as not getting enough exercise, are some of them. Depending on the tumor stage and biology, many treatment techniques, including chemotherapy, radiation, surgery, or immunotherapy, and hormonal therapy, are utilized to manage breast cancer in Kenya. It has been demonstrated that receiving care for breast cancer improves overall survival, survival without disease, complete remission, and lowers morbidity and mortality. Despite these substantial advantages, the prognosis for breast cancer treatment is poor. Due to the lack of healthcare resources and the imbalance in access to care and facilities, the situation is worse in Kenya.

Market Dynamics

Market Growth Drivers

Due to an increase in breast cancer cases in Kenya, it is projected that the market for breast cancer therapeutics would expand. Kenya's breast cancer therapeutics market is also expanding due to the increasing geriatric population and changing lifestyle habits.

Market Restraints

The Kenya breast cancer therapeutics market is being constrained by a decline in healthcare spending and a subpar healthcare infrastructure. A decline in the Kenya breast cancer therapeutics market could also be attributed to less favorable reimbursement criteria for breast cancer.

Competitive Landscape

Key Players

Cosmos Pharmaceutical (KEN)
Dawa (KEN)
Regal Pharmaceuticals (KEN)
Sphinx Pharmaceuticals (KEN)
Pfizer
Celgene
Sanofi
Teva Pharmaceutical
Bristol-Myers Squibb
Merck

Healthcare Policies and Regulatory Landscape

The principal health insurance company in Kenya is called the National Hospital Insurance Fund (NHIF), and its goal is to make it feasible for every Kenyan to get access to high-quality, reasonably priced medical care. In addition to the Universal Health Coverage (UHC) program, which strives to offer accessible healthcare to all residents, the National Health Insurance Fund (NHIF) also offers financial support to its members for medical treatment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.